Geneva, Jan. 12 -- International Clinical Trials Registry received information related to the study (ChiCTR2500115224) titled 'Safety Study of Anti-PD-1 Antibody Combined with Anti-CTLA-4 Antibody in the Treatment of Primary Liver Cancer' on Dec. 24, 2025.
Study Type: Interventional study
Study Design:
Non randomized control
Primary Sponsor: Chuzhou First People's Hospital
Condition:
HCC
Intervention:
Experimental group:PD-1 combined with CTLA-4 immunotherapy
Recruitment Status: Not Recruiting
Phase: 4
Date of First Enrollment: 2025-12-24
Target Sample Size: Experimental group:30;Control group:30;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=301720
Published by HT Digi...